ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (16), the stock would be worth $0.59 (97% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 606.1 | $22.45 |
0%
|
| Industry Average | 16 | $0.59 |
-97%
|
| Country Average | 21.9 | $0.81 |
-96%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
3.8B USD | 606.1 | 9.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -2 855 158.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 24 | 89.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 23 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 24 | 19.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -480.6 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 34.2 | 27.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 20 | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 159.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 35.5 | 29.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.1 |
| Median | 21.9 |
| 70th Percentile | 36.5 |
| Max | 3 188 432.5 |
Other Multiples
ACADIA Pharmaceuticals Inc
Glance View
ACADIA Pharmaceuticals Inc., nestled in the heart of biopharmaceutical innovation, has carved a niche as a trailblazer in tackling neurological and central nervous system disorders. The company's journey pivotally surrounds its flagship product, NUPLAZID (pimavanserin), which was approved by the FDA in 2016. Designed to address the psychosis associated with Parkinson’s disease, NUPLAZID opened new therapeutic doors, addressing a critical unmet medical need and improving patients’ quality of life. Leveraging this milestone, ACADIA has strategically focused on developing innovative therapies, extending its research into potential treatments for schizophrenia, major depressive disorders, and other neuropsychiatric conditions, thus widening its revenue streams and research portfolios. The company's financial engine is fueled primarily by sales of NUPLAZID, which has stood as a steady pillar in generating revenues. To amplify its growth trajectory, ACADIA emphasizes expanding NUPLAZID's usability through rigorous clinical trials aimed at securing approvals for additional indications. Concurrently, the company actively explores partnerships and acquisitions to broaden its pipeline, inaugurating an aspirational pursuit to revolutionize mental health treatment. With a keen eye on demographic trends and the increasing prevalence of CNS disorders globally, ACADIA Pharmaceuticals aligns its business operations not just on curing ailments, but on redefining health paradigms, thus reinforcing its sustainability in the competitive biopharmaceutical landscape.
